Metsera, Inc. Files 8-K: Material Agreement and Other Events

TL;DR

Metsera just signed a big deal, check the 8-K for details.

AI Summary

On November 7, 2025, Metsera, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Metsera, Inc. is incorporated in Delaware and its principal executive offices are located at 3 World Trade Center, New York, NY.

Why It Matters

This 8-K filing indicates a significant new agreement for Metsera, Inc., which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Metsera, Inc. (company) — Registrant
• November 7, 2025 (date) — Date of earliest event reported
• 3 World Trade Center (location) — Principal Executive Offices Address
• New York, New York (location) — Principal Executive Offices City and State
• 10007 (zip_code) — Principal Executive Offices Zip Code

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share MTSR The Nasdaq Global Se
• $47.50 — s defined in the Merger Agreement) from $47.50 to $65.60 in cash per share of Company
• $65.60 — in the Merger Agreement) from $47.50 to $65.60 in cash per share of Company Common Sto
• $22.50 — ntingent value right ("CVR") from up to $22.50 to up to $20.65 per share of Company Co
• $20.65 — ight ("CVR") from up to $22.50 to up to $20.65 per share of Company Common Stock in ca
• $5.00 — s: a. Clinical Trial Milestone: From $5.00 to $4.60 per CVR, without interest and
• $4.60 — Clinical Trial Milestone: From $5.00 to $4.60 per CVR, without interest and less any
• $7.00 — b. Mono FDA Approval Milestone: From $7.00 to $6.40 per CVR in cash, without inter
• $6.40 — o FDA Approval Milestone: From $7.00 to $6.40 per CVR in cash, without interest and l
• $10.50 — ombination FDA Approval Milestone: From $10.50 to $9.65 per CVR in cash, without inter
• $9.65 — FDA Approval Milestone: From $10.50 to $9.65 per CVR in cash, without interest and l
• $190 million — ccept a Superior Company Proposal, from $190 million to $265 million; iv. require Parent,
• $265 million — Company Proposal, from $190 million to $265 million; iv. require Parent, with respect to
• $1.5 b — quirement for Parent to expend at least $1.5 billion, as may have been adjusted pursua

Filing Documents

• d50740d8k.htm (8-K) — 46KB
• d50740dex21.htm (EX-2.1) — 148KB
• d50740dex991.htm (EX-99.1) — 17KB
• 0001193125-25-273292.txt ( ) — 381KB
• mtsr-20251107.xsd (EX-101.SCH) — 3KB
• mtsr-20251107_lab.xml (EX-101.LAB) — 18KB
• mtsr-20251107_pre.xml (EX-101.PRE) — 11KB
• d50740d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including information about, among other topics, Parent's proposed acquisition of Metsera, Metsera's pipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties relating to Parent's proposed acquisition of Metsera include, among other things, risks relating to Parent's litigation against the Company, including expenses from defending the litigation, potential damages or other losses resulting from the litigation, the impact of the litigation on the Company, its business and the market price of the Company's common stock; risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain the requisite vote by Metsera stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that more competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including Metsera's ability to attract and retain highly qualified management and other clinical and scientific personnel; negative effects of th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. METSERA, INC. Date: November 10, 2025 By: /s/ Matthew Lang Matthew Lang Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR